Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Archive ouverte

Guglielmetti, Lorenzo | Günther, Gunar | Leu, Claude | Cirillo, Daniela | Duarte, Raquel | Garcia-Basteiro, Alberto | Goletti, Delia | Jankovic, Mateja | Kuksa, Liga | Maurer, Florian | Méchaï, Frédéric | Tiberi, Simon | van Leth, Frank | Veziris, Nicolas | Lange, Christoph

Edité par CCSD ; European Respiratory Society -

International audience. Rifapentine, a synthetic derivate of rifampicin which was developed in 1965, has interesting pharmacological properties, including a long terminal half-life (13 h, compared to 2-3 h for rifampicin) and promising bactericidal activity against Mycobacterium tuberculosis. Despite being approved in 1998 by the US Food and Drug Administration (FDA) for the treatment of pulmonary tuberculosis, its global use has been limited by unavailability. In the past decade, new evidence has emerged to define rifapentine as a key component for treatment of active disease and latent infection with M. tuberculosis (LTBI).

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion